Skip to content
Delayed ~15 min

LCTX LINEAGE CELL THERAPEUTICS INC

Permanent stock page ↗

Health Care · Russell 2000

Next earnings: Thu 12 Nov 2026 · after market close

What 9 analyst firms say about LINEAGE CELL THERAPEUTICS INC: their latest ratings, price targets and how far the stock is from them. How it works

1.02 USD+0.04 (+3.75%) today
Price as of 6 Nov 16:00 ET

Analyst window: Latest analyst report within last 1 year

Analyst view · last 1Y

+404.2%to the avg target 5.14 USD+4.12 USD
Buy 7 · Hold 2 · Sell 0

9 rated views · 9 analyst/firm records · 9 firms

Latest report3 Sep 2026avg report date 13 May
Target rangePrice is below every target

Radar score

  • Russell 2000 · Top Picks · 6MNot scored · Fewer than 4 price targets in the last 6 months (3)
  • Russell 2000 · Safest consensus · 6MNot scored · Fewer than 4 price targets in the last 6 months (3)

Recent analyst activity · last 90 days

Our tracked history has 1 report on LCTX from 1 analyst firm in the last 90 days (9 firms in the past year).

Comparing each firm's latest target with its previous one: 1 left it unchanged.

No firm's latest available rating differs from its previous one.

Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.

FirmAnalystLatest ratingReport dateLatest target (USD)
B Riley SecuritiesMayank MamtaniBuy3 Sep 20264.00 USD
BairdJack K AllenBuy1 Apr 20265.00 USD
Canaccord GenuityJohn L NewmanBuy28 Apr 20269.00 USD
Craig-HallumAlbert LoweBuy6 Mar 20263.00 USD
D Boral CapitalPatrick MccannBuy21 May 20263.00 USD
H.C. WainwrightJoseph PantginisBuy14 Jul 20269.00 USD
Maxim GroupMichael OkunewitchBuy15 Mar 20263.00 USD
Raymond JamesSean MccutcheonHold12 May 2026—
Data feed RESEARCHResearch TeamHold15 Jun 2026—

Partial coverage · checked 6 Nov (6 Nov 2026, 07:03 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.